MedStar Authors catalog › Details for: Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry).
Normal view MARC view ISBD view

Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS premier registry).

by Gaglia, Michael AJ; Wang, John; Gai, Jiaxiang; Torguson, Rebecca; Waksman, Ron.
Citation: Cardiovascular Revascularization Medicine. 18(1):16-21, 2017 Jan - Feb.Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: 2017ISSN: 1878-0938.Full author list: Gaglia MA Jr; Goodroe R; Mishkel G; Gharib W; Tabrizchi A; Nazif T; Wang J; Scott T; Lopez M; Steinberg D; Gai J; Torguson R; Waksman R.UI/PMID: 27866748.Subject(s): Aged | Cardiovascular Agents/ad [Administration & Dosage] | Chi-Square Distribution | Coronary Artery Disease/dg [Diagnostic Imaging] | *Coronary Artery Disease/th [Therapy] | Coronary Thrombosis/et [Etiology] | *Drug-Eluting Stents | Everolimus/ad [Administration & Dosage] | Female | Humans | Kaplan-Meier Estimate | Male | Middle Aged | Multivariate Analysis | Myocardial Infarction/et [Etiology] | Percutaneous Coronary Intervention/ae [Adverse Effects] | *Percutaneous Coronary Intervention/is [Instrumentation] | Proportional Hazards Models | Prosthesis Design | Registries | Retrospective Studies | Risk Factors | Time Factors | Treatment Outcome | United StatesInstitution(s): MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment(s): MedStar Union Memorial HospitalActivity type: Journal Article.Medline article type(s): Comparative Study | Journal Article | Multicenter StudyDigital Object Identifier: (Click here) Abbreviated citation: Cardiovasc Revasc Med. 18(1):16-21, 2017 Jan - Feb.Local Holdings: Available in print through MWHC library: 2002 - present.Abstract: BACKGROUND/PURPOSE: Drug-eluting stents (DES) reduce in-stent restenosis and repeat revascularization in comparison to bare metal stents. Individual DES vary, however, in regard to rates of restenosis and stent thrombosis; they also differ in regard to their platform and physical characteristics. The Promus Premier was designed to improve the performance of the Promus Element, with respect to conformability, trackability, and avoidance of longitudinal stent deformation; there is little published data, however, on clinical outcomes with Promus Premier.Abstract: METHODS: We performed a registry study that compared 952 patients who underwent percutaneous coronary intervention with Promus Premier to 595 patients who received Taxus Liberte and 600 patients who received Xience V for a variety of indications. The primary endpoint was a composite of all-cause mortality, definite or probable stent thrombosis, myocardial infarction, and target vessel revascularization (TVR-MACE). Kaplan-Meier analysis and Cox proportional hazards regression were performed in order to compare the three stents in regard to outcomes at 1year.Abstract: RESULTS: Procedural success was highest with Premier (99.4%) when compared to Xience V (98.0%) and Taxus Liberte (97.3%; p<0.001). Unadjusted survival analysis showed that TVR-MACE was less frequent with Premier in comparison to Taxus Liberte (p=0.003), and similar frequency in comparison to Xience V (p=0.16). Following multivariable adjustment, and using Xience V as the reference, there was only a borderline association of Promus Premier and lower rates of TVR-MACE (HR 0.69, 95% CI 0.45-1.04; p=0.075).Abstract: CONCLUSION: Promus Premier demonstrates excellent procedural success rates and real-world outcomes that are similar to Xience V.Abstract: Copyright © 2016. Published by Elsevier Inc.

Powered by Koha